Skip to main content

SC-CAR.GPC3xIL15.21 CAR T cells

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

  • RegistryNCT07148050
  • PhasePhase 1
  • StatusRecruiting
  • ConditionSolid Tumor (Excluding CNS)
  • SponsorSeattle Children's Hospital
How IMPACT worksNCT071480501 min

What the film says

Read the transcript

Some childhood solid tumors, liver cancers, Wilms tumor, rhabdomyosarcoma, share a protein called glypican-3. When they return, few options remain.

The idea: aim engineered T cells at that protein, give them their own fuel, and build in an off switch.

At Seattle Children's, a child's T cells receive a receptor for glypican-3 together with genes for interleukin-15 and interleukin-21, signals that help them persist inside a solid tumor, where CAR T cells usually fade. In the lab, that combination killed tumor cells better than the receptor alone. A safety gene lets doctors eliminate the cells with a drug if side effects demand it.

IMPACT is an early safety study, ages one to twenty-six. Michelle Choe leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT07148050

    GPC3 on pediatric liver cancers, Wilms, rhabdomyosarcoma, rhabdoid, yolk sac; GPC3 CAR + IL-15 + IL-21 for growth and persistence; Lab: better killing with IL-15/IL-21 than GPC3-CAR alone; Inducible caspase-9 suicide gene (+1 more lines)

The drug

What is being tested.

Autologous SC-CAR.GPC3xIL15.21 T cell products infusion

Study Overview This study is testing a different treatment which uses the body's own immune system to recognize and kill the cancer cells, called chimeric antigen receptor (CAR) T cells. Some solid tumors express a specific type of molecule called glypican-3 or GPC3. We are able to insert a new gene (a piece of DNA that contains a set of instructions for the body) into T cells which are a type of immune system cell.

This is how we make CAR T cells: We will insert a gene that will program the CAR T cell to recognize GPC3 to make GPC3-CAR T cells. To make GPC3-CAR T cells more effective against tumor cells, we also added two genes called IL15 and IL21 which help CAR T cells grow better and stay in the blood longer. We think that this will kill tumors better.

The study

How the trial runs.

This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified to co-express a GPC3-specific chimeric antigen receptor (CAR), interleukin (IL)-15 and IL-21 as well as the inducible caspase 9 (iC9) suicide gene (SC-CAR.GPC3xIL15.21 T cells).

A child or young adult meeting all eligibility criteria and meeting none of the exclusion criteria will have a blood sample collected, which will be used to bioengineer the CAR T cells targeting their tumor.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Procurement Eligibility
  • Diagnosis of a solid tumor expressing GPC3
  • Lansky or Karnofsky score of >=60%
  • Life expectancy of >16 weeks
  • Informed consent explained to, understood by and signed by patient/guardian.
  • For patients with hepatocellular carcinoma only:

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.